BRAF and non-small cell lung carcinoma: While the predictive value of wild-type KRAS genotype for identifying patients who will benefit from anti-EGFR monoclonal antibodies treatment is now well established in metastatic colorectal cancer, the significance of KRAS and BRAF mutations in NSCLC is not yet comparably clear [14–17].